parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (589 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	8 Parkinson's papers of 118	0.71
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 8334

DPYSL2 in dopamine neurons, braak+0.25 (p 0.508) → -0.26 (p 0.493)receipt 8341
DPYSL2 in oligodendrocytes, braak+0.25 (p 0.514) → -0.38 (p 0.309)receipt 8340

receipt 8341: DPYSL2 in dopamine neurons, braak

power: full sample +0.05 (p 0.834, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.00 (p 0.997, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.02 (p 0.949, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.16, sign flips 3; without severely affected donors +0.05 (p 0.834, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DPYSL2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 8340: DPYSL2 in oligodendrocytes, braak

power: full sample -0.10 (p 0.690, n 18), 95% CI -0.54 to +0.38. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.02 (p 0.928, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.03 (p 0.915, n 18). could be the mix.
skeptic: leave-one-out range -0.24 to -0.01, sign flips 0; without severely affected donors -0.10 (p 0.690, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DPYSL2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts